Raymond Kaempfer
Corporate Officer/Principal chez European Molecular Biology Organization
Postes actifs de Raymond Kaempfer
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| European Molecular Biology Organization | Corporate Officer/Principal | - | - |
Historique de carrière de Raymond Kaempfer
Anciens postes connus de Raymond Kaempfer
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - | - |
| The Hebrew University of Jerusalem | Corporate Officer/Principal | - | - |
Atox Bio Ltd.
 Atox Bio Ltd. BiotechnologyHealth Technology Atox Bio, Inc. provides novel immune modulators for critically ill patients with severe infections. The firm discovers and develops novel immune modulators for critically ill patients with severe infections. Its main product is AB103, a novel immune modulator. The company was founded by Raymond Kaempfer and Gila Arad in 2003 and is headquartered in Ness Ziona, Israel. | Directeur/Membre du Conseil | 01/01/2003 | - |
| Directeur Technique/Scientifique/R&D | 01/01/2003 | - | |
| Fondateur | 01/01/2003 | - |
Formation de Raymond Kaempfer
| Massachusetts Institute of Technology | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 3 |
| Israël | 3 |
| Allemagne | 2 |
Opérationnelle
| Corporate Officer/Principal | 3 |
| Director/Board Member | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectorielle
| Consumer Services | 3 |
| Finance | 2 |
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 2 |
|---|---|
| European Molecular Biology Organization | |
Atox Bio Ltd.
Atox Bio Ltd. BiotechnologyHealth Technology Atox Bio, Inc. provides novel immune modulators for critically ill patients with severe infections. The firm discovers and develops novel immune modulators for critically ill patients with severe infections. Its main product is AB103, a novel immune modulator. The company was founded by Raymond Kaempfer and Gila Arad in 2003 and is headquartered in Ness Ziona, Israel. | Health Technology |
- Bourse
- Insiders
- Raymond Kaempfer
- Expérience
